Parkinson’s UK is pleased to announce the release of the next tranche of funding to continue our collaboration with NRG Therapeutics Ltd to develop novel drugs that can protect mitochondria and thereby slow the progression of Parkinson’s.  
 
Mitochondria are tiny batteries present inside cells that provide the essential energy they need to survive and function. Prev...

Parkinson's Foundation grants £200,000 to Parkinson's UK to invest in the Parkinson's Virtual Biotech.

Each year, Parkinson's UK, their supporters and partners invest more than £4 million into the Parkinson's Virtual Biotech to rapidly develop and test the most promising research findings with the aim of turning them into treatments that will transform the lives of pe...

The Parkinson’s Virtual Biotech is pleased to announce the appointment of eminent expert Dr Richard Seabrook PhD MBA as a non-executive Director of NRG Therapeutics.

Richard brings over 25 years of experience in scientific translation working with companies, charities and universities to accelerate drug development. 

During his time at The Wellcome Trust Richard establ...

A pioneering clinical trial will investigate the use of cannabidiol (CBD) - a compound found in the cannabis plant - in people with Parkinson’s-related psychosis.

Parkinson’s UK, the largest charitable funder of Parkinson's research in Europe, is partnering with scientists at King’s College London and investing £1.2 million in the phase II clinical trial. 

This is the...

“This is an exciting new approach that could rescue defective mitochondria inside neurons to prevent dysfunction and degeneration of dopamine-producing brain cells." - Richard Morphy, Drug Discovery Manager

Parkinson’s UK have partnered with NRG Therapeutics to find a drug that could protect dopamine cells damaged by the condition

Charity Parkinson’s UK is partnering with NRG Therapeutics Ltd to discover and develop a potential drug that could safeguard dopamine cells that are damaged by Parkinson’s and slow down the progression of the condition.

Building on recent discov...